Trial Profile
A trial to study long-term, whole population 'real-world' clinical outcomes of ranibizumab therapy in treatment-naive eyes for neovascular age-related macular degeneration
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Jun 2016
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 09 Jun 2016 New trial record